Rita Numerof (@RitaNumerof) profile picture

President @NAIconsulting. Helping businesses across healthcare define/implement strategies to win in dynamic markets.

St Louis, MO
Joined January 2016
Photo by Rita Numerof (@RitaNumerof)Photo by Rita Numerof (@RitaNumerof)Photo by Rita Numerof (@RitaNumerof)Photo by Rita Numerof (@RitaNumerof)Photo by Rita Numerof (@RitaNumerof)Photo by Rita Numerof (@RitaNumerof)Photo by Rita Numerof (@RitaNumerof)
Market-driven healthcare is the future. My new book out today-"Bringing Value to Healthcare" youtu.be/L0ypIF5Mf8s
7
32
3
57
Healthcare leaders no longer need to diagnose the problem – they need to execute change. In my latest column, I outline a framework for transformation built on a clear case for action, a concrete vision and the participation needed to make it happen. nai-consulting.com/beyond-di…
29
The recent hearing on hospital prices sent a clear signal: bipartisan patience with the current HCD model is wearing thin. Rising costs, consolidation and weak value transparency are now central questions in D.C. Incremental reform is no longer enough. nai-consulting.com/hospital-…
1
24
Big pharma cut 22,000+ jobs in 2025 as a $300B patent cliff looms. Periodic restructuring is not unusual, but the scale & simultaneity of these layoffs reveals a deeper industry shift and why evidence has become the central determinant of value. Read more:bit.ly/4vjNk9Z
24
.@Pharmacy_Times: The FDA’s move to expand RWE in clinical trials is an important step forward. Raising the evidentiary bar won’t stifle innovation—it ties price to value and helps ensure the U.S. continues to lead in both innovation and accountability. bit.ly/4rAB8zH
1
39
AI is rapidly becoming embedded across the pharmaceutical industry, but until organizations become more disciplined about defining the questions they need answered, even the most sophisticated AI capabilities will underperform. Read More: bit.ly/49u7vI6
25
Cost pressure, access demands and accountability expectations are accelerating disruption across HCD and insurance. As 2026 approaches, shrinking fee-for-service viability and rising consumer expectations mean incremental adjustments will not be enough. bit.ly/4j8otjY
22
Policy pressure is reshaping the pharma landscape, and 2026 will require sharper evidence and clearer value communication to stay competitive. Our 2026 Global Pharma Outlook breaks down the key opportunities and challenges ahead. Read more: bit.ly/4aYMvf3
32
A 43-day shutdown over temporary ACA subsidies revealed the bigger issue: a system with misaligned incentives. Leaders need to shift from managing crises to designing a system anchored in accountability, competition and improving care at affordable prices. bit.ly/3K81mZK
58
Following @Pfizer & @AstraZeneca’s new deals with the Trump Admin, TrumpRx.gov marks a significant shift—elevating DTC pricing to a national priority and challenging pharma’s opaque model to restore a rational link between cost and value. bit.ly/3WBPXnG
46
The number of osteoporosis bone fractures is expected to increase by 68% from 1.9 million (2018) to 3.2 million in 2040, impacting patient quality of life and healthcare costs. Ask your doctor about screenings and prevention. @Amgen @bonehealthBHOF @HealthyWomen
1
27